BeiGene (BGNE) Financial Analysis & Valuation | Quarter Chart
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to ... more
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and comme... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $20.21B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | John V. Oyler |
| IPO Date | 2016-02-03 | CAGR | 67.26% |
| Employees | 10,600 | Website | www.beigene.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BGNE chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $16.58B | P/E | -22.55 | Forward P/E | — | PEG | -0.45 |
| P/S | 7.04 | P/B | 11.63 | P/CF | 40.31 | P/FCF | 32.91 |
| Sales | $6.13B | Sales 1Y | 34.35% | Sales 3Y | 238.47% | Sales 5Y | 547.17% |
| EPS | $-8.19 | EPS 1Y | 493.76% | EPS 3Y | -215.45% | EPS 5Y | -440.18% |
| Sales QoQ | 12.66% | EPS QoQ | -91.84% | Sales QoQ Avg | 6.78% | EPS QoQ Avg | 29.91% |
| Gross Margin | 87.82% | Operating Margin | 15.05% | Profit Margin | 10.68% | ROCE | 13.14% |
| ROA | 7% | ROE | 14% | Altman Z Score | 3.51 | Piotroski Score | 6 |
| Current Ratio | 3.4 | Quick Ratio | 3.06 | Cash Ratio | 2.41 | Op. CF Ratio | 0.22 |
| Debt/Equity | 0.22 | Debt/Assets | 0.12 | Lt Debt/Equity | 0.18 | Lt Debt/Cap. | 0.15 |
| Intrst Cov. | 9.9 | Inventory Turnover | 1.02 | Asset Turnover | 0.67 | Receivables Turnover | 5.75 |
| Enterprise Value | $16.58B | P/E Ratio | -22.55 |
| Forward P/E | — | PEG Ratio | -0.45 |
| P/S Ratio | 7.04 | P/B Ratio | 11.63 |
| P/CF Ratio | 40.31 | P/FCF Ratio | 32.91 |
| EPS | $-8.19 | EPS Growth 1Y | 493.76% |
| EPS Growth 3Y | -215.45% | EPS Growth 5Y | -440.18% |
| Revenue Growth 1Y | 34.35% | Gross Margin | 87.82% |
| Operating Margin | 15.05% | Profit Margin | 10.68% |
| ROE | 14% | ROA | 7% |
| ROCE | 13.14% | Current Ratio | 3.4 |
| Quick Ratio | 3.06 | Cash Ratio | 2.41 |
| Debt/Equity | 0.22 | Interest Coverage | 9.9 |
| Altman Z Score | 3.51 | Piotroski Score | 6 |
BeiGene (BGNE) valuation & financials
BeiGene (BGNE) has a market capitalization of $20.21B and trades at a price-to-earnings ratio of -22.6. It operates in the Healthcare sector (Biotechnology).
BeiGene's revenue grew +34.3% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)